Company: ARMP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077648
Chunk: 2

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 2
---
 time to time, we may sell up to an aggregate
of $100,000,000 of our common stock, preferred stock, debt securities, warrants or units in any combination of the foregoing, in amounts,
at prices and on terms described in one or more supplements to this prospectus. We may also authorize one or more free writing prospectuses
to be provided to you in connection with these offerings.

Our common stock is traded on the New York Stock
Exchange (the “NYSE”) American under the trading symbol “ARMP.” On August 11, 2025, the last reported sale price
of our common stock on the NYSE American was $2.36.

The preferred stock, debt securities, warrants
and units described in this prospectus have not been approved for listing on any market or exchange, and we have not made any application
for such listing.

This prospectus describes the general terms of
the securities we may offer and the general manner in which we may offer these securities. Each time we sell securities described herein,
we will provide prospective investors with a supplement to this prospectus that will contain specific information about the terms of that
offering, including the specific amounts, prices and terms of the securities offered. Such prospectus supplements may also add, update
or change information contained in this prospectus. The applicable prospectus supplement will contain information, where applicable, as
to any other listing on the NYSE American or any other securities market or other exchange with respect to the securities covered by such
prospectus supplement.

Our principal executive offices are located at
5005 McConnell Avenue, Los Angeles, California 90066, and our telephone number at that address is (310) 665-2928.

You should read this prospectus and any prospectus
supplement carefully before you invest.

<div align='center'>- 2 -</div>

INVESTING IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES REFERENCED UNDER THE HEADING “RISK FACTORS” ON PAGE 8 OF THIS PROSPECTUS AND “ITEM 1A—RISK FACTORS” OF OUR MOST RECENT ANNUAL REPORT ON FORM 10-K OR QUARTERLY REPORT ON FORM 10-Q THAT IS INCORPORATED BY REFERENCE IN THIS PROSPECTUS, AS WELL AS THOSE CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT AND